Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.

TRANSFUSION CLINIQUE ET BIOLOGIQUE, an esteemed journal published by Elsevier France - Éditions Scientifiques Médicales Elsevier, has been a pivotal resource in the fields of transfusion medicine, biochemistry, and hematology since its inception in 1994. With a strong commitment to advancing scientific knowledge, this journal provides a platform for high-quality research and clinical studies aimed at improving patient care and outcomes in transfusion practices. Although categorized in Q3 and Q4 quartiles across multiple categories in Biochemistry and Medicine for 2023, the journal holds significant potential for growth and impact within the scientific community. While it currently does not offer open access options, its indexing in reputable databases ensures visibility and reach among professionals and researchers. As the field evolves, TRANSFUSION CLINIQUE ET BIOLOGIQUE aims to continue fostering innovation and collaboration, making it a valuable tool for anyone involved in medical, biochemical, and hematological research.

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.

British Journal of Haematology, published by Wiley, is a leading journal in the field of hematology, with an impressive impact factor reflecting its significance in the medical research community. Established in 1955, the journal has consistently contributed to advancing knowledge in hematology, currently holding a prestigious Q1 ranking in the Scopus category of Hematology, placing it in the top 18% of the field. The journal encompasses a broad range of topics including clinical and laboratory aspects of blood disorders and hematological malignancies, making it an essential resource for hematologists, researchers, and healthcare professionals. With its commitment to publishing top-tier research and clinical studies, the British Journal of Haematology plays a critical role in shaping treatment approaches and improving patient outcomes worldwide. Please note that this journal does not offer Open Access options, ensuring that published content is rigorously curated for quality and relevance.

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

JOURNAL OF CLINICAL PATHOLOGY, published by BMJ PUBLISHING GROUP, stands at the forefront of advancements in the field of clinical pathology, offering a platform for groundbreaking research and insights from 1948 to the present. With an impressive impact factor and categorized as Q1 in both Medicine (miscellaneous) and Pathology and Forensic Medicine for 2023, the journal holds a distinguished position in the academic community, ranking 22nd out of 208 journals in its category on Scopus and representing the 89th percentile. While the journal does not currently offer open access, it remains a vital resource for researchers, healthcare professionals, and students seeking to stay current with innovative methodologies, clinical techniques, and diagnostic advancements. Located in London, United Kingdom, the journal aims to bridge the gap between laboratory findings and clinical practice, emphasizing the importance of evidence-based pathology in improving patient care and treatment outcomes. Engage with the JOURNAL OF CLINICAL PATHOLOGY to enhance your understanding and contribute to the evolving landscape of clinical pathology research.

Anemia is a distinguished open-access journal published by HINDAWI LTD, focusing on the intricate and vital field of hematology and related disciplines. Since its inception in 2010, this journal has been dedicated to advancing our understanding of blood disorders, with a particular emphasis on anemia, through the dissemination of high-quality research that is freely accessible to a global audience. The journal's evolving scope from its founding through 2024 embodies its commitment to include the latest breakthroughs and methodologies in cell biology and hematological research. With its presence in prestigious databases and a tiered ranking that places it in the Q3 category in Hematology and Q4 in Cell Biology as of 2023, Anemia serves as an invaluable resource for researchers, clinicians, and students alike. The journal is indexed with a respectable position in Scopus, ranking 52 out of 137 in Hematology, highlighting its growing influence in the medical and scientific communities. With continued emphasis on open access, Anemia not only fosters collaborative research but also ensures that crucial findings reach those who need them most, enhancing educational outcomes and clinical practices worldwide.

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

Transfusionsmedizin is a premier journal dedicated to the field of transfusion medicine, published by the renowned GEORG THIEME VERLAG KG. With an ISSN of 2191-8805 and an E-ISSN of 2191-8813, this journal serves as a vital platform for disseminating cutting-edge research and clinical advancements in blood transfusion practices. Although it operates under a subscription model, the journal is committed to high-quality peer-reviewed content that addresses contemporary challenges and innovations in transfusion therapy. By fostering dialogue among researchers, clinicians, and students, Transfusionsmedizin aims to advance patient care and enhance the safety and efficacy of transfusion practices globally. Its contributions are essential for professionals engaged in transfusion science, hematology, and related medical fields, solidifying its reputation as a critical resource for staying abreast of the latest developments in transfusion research.

VOX SANGUINIS is a distinguished peer-reviewed journal in the fields of Hematology and Medicine, published by Wiley, a leading academic publisher based in the United Kingdom. With a rich history dating back to its inception in 1952, this journal has consistently provided a platform for innovative research and insightful reviews, advancing the understanding of blood-related disorders and therapies. As evidenced by its robust performance—ranking #57 out of 137 in Scopus for Medicine in Hematology and holding a Q2 classification in both Hematology and miscellaneous Medicine categories—VOX SANGUINIS is recognized for its significant contributions to the scientific community. This journal serves as a vital resource for researchers, professionals, and students alike, fostering knowledge exchange and collaboration within the field. With its ongoing commitment to quality and integrity, VOX SANGUINIS continues to shape the future of hematological research well into 2024 and beyond.